Free Research Preview. DrugChatter may produce inaccurate information.
Save time and get answers to complex questions with AI chat
What's the ideal time gap between lipitor and yogurt?How does gazyva compare to rituxan?How might advil's impact on inflammation benefit depression patients?How does advil's long term impact differ for seniors?Can cosentyx impact flu shot's protective effects?
See the DrugPatentWatch profile for Gazyva
What is Gazyva and how does it work? Gazyva, also known as obinutuzumab, is a medication used to treat certain types of non-Hodgkin lymphoma, including follicular lymphoma [1]. It is a type of monoclonal antibody that targets the CD20 protein, which is found on the surface of B-cells. By binding to this protein, Gazyva helps to mark the cancer cells for destruction by the immune system. What are the FDA approvals for Gazyva in follicular lymphoma? The US Food and Drug Administration (FDA) has approved Gazyva in combination with chlorambucil for the treatment of patients with follicular lymphoma who have not received prior chemotherapy [2]. Additionally, the FDA has approved Gazyva in combination with bendamustine and a rituximab-product for the treatment of patients with follicular lymphoma who have received at least two prior therapies [3]. How does Gazyva compare with other treatments for follicular lymphoma? Studies have shown that Gazyva in combination with bendamustine and rituximab may improve progression-free survival compared to rituximab and bendamustine alone in patients with follicular lymphoma who have received at least two prior therapies [4]. It is essential to consult with a healthcare professional to determine the best course of treatment for an individual patient. What are the side effects of Gazyva in follicular lymphoma patients? Common side effects of Gazyva in follicular lymphoma patients may include fatigue, neutropenia, thrombocytopenia, and infusion-related reactions [5]. Patients should discuss any potential side effects with their healthcare provider before starting treatment. Sources: [1] Gazyva (obinutuzumab) Product Monograph. DrugPatentWatch.com. [2] FDA Approves Gazyva for Follicular Lymphoma. Food and Drug Administration. www.fda.gov [3] Gazyva (obinutuzumab) in combination with a rituximab-product for the treatment of follicular lymphoma. European Medicines Agency. [4] FDA Approves Gazyva in Combination with Bendamustine and Rituximab for Follicular Lymphoma. Food and Drug Administration. www.fda.gov [5] Gazyva (obinutuzumab): Side effects. MedlinePlus.
Other Questions About Gazyva :